than the steady state plasmatic concentration. These data suggest that tipifarnib efficacy could be tested in ETP-ALL patients using well-tolerated dosages. Sensitivity to tipifarnib was recently associated with RASGRP1/APTX expression ratio in acute myeloid leukemia, 8 but we found no significant correlation between the expression of these predictor signature and drug sensitivity. Therefore, the mechanism of action of farnesyltransferase inhibitors in pediatric T-ALL requires further investigations, as confirmed by early studies that showed no correlation between the presence of Ras mutations and the response to tipifarnib. 6 In fact, even if farnesylation is the dominant class of post-translational modification that activates RAS, there are other types of prenylation not inhibited by farnesyltransferase inhibitors that allow RAS attachment to the cell membrane and its participation in signal transduction. 6 Indeed, we can suppose that tipifarnib activity in ETP-ALL cells is at least in part, even if not completely, explained by NF1 inactivation. More experimental data are needed to clarify the real sensitivity of ETP-ALL cells to tipifarnib. This is the first report showing a case of pediatric ETP-ALL with high sensitivity to tipifarnib that could be related to a specific gene (NF1) deletion. Thus, additional studies are needed to analyze NF1 role in patients with ETP-ALL and tipifarnib sensitivity to improve the outcome of this newly identified high-risk subtype of ALL.
The aim of the IFM2005-01 phase 3 multicenter study (EudraCT 2005-000537-38, Clinicaltrials.gov NCT00200681) was to compare prospectively efficacy and safety of bortezomib and dexamethasone with vincristine-doxorubicin-dexamethasone (VAD) as induction before autologous stem cell transplantation (ASCT) in patients with previously untreated myeloma less than 66 years of age. The primary end point was post-induction complete response and near-complete response rate. An important issue raised by this study was that of stem cell collection in the bortezomib-dexamethasone arm.
1,2
Patients were centrally randomized (1:1:1:1) to receive VAD induction plus no consolidation (arm A1), VAD plus dexamethasone, cyclophosphamide, etoposide and cis-platinum consolidation (A2), bortezomib-dexamethasone plus no consolidation (B1) or bortezomib-dexamethasone plus dexamethasone, cyclophosphamide, etoposide and cis-platinum A total of 493 patients were enrolled and 482 were randomized; 242 received VAD induction (arm A: 121 A1, 121 A2) and 240 received bortezomib-dexamethasone (arm B: 121 B1, 119 B2). A better response rate was observed in bortezomibdexamethasone arm. Results for both efficacy and toxicity of induction therapy will be reported in depth elsewhere. 3 A total of 441 out of 482 patients were evaluable for stem cell collection, 216 in VAD and 225 in bortezomib-dexamethasone arms, respectively. Overall, 41 randomized patients did not receive G-CSF for stem cell collection due to progressive disease (8 cases), toxic deaths (8), severe adverse events (17), patient's refusal (2), poor performance status (4), diagnosis of lung cancer during treatment (1), diagnosis of amyloidosis during treatment (1). After one mobilization with G-CSF, median yields of 8.50 and 6.80 Â 10 6 CD34 þ cells/kg were obtained from patients receiving VAD and bortezomib-dexamethasone, respectively, with a mean of 1.63 and 2.05 aphereses (Table 1) . In total, 98 and 97% of patients, respectively, had yields 42 Â 10 6 cells/kg, and 11 and 23%, respectively, had yields o5 Â 10 6 cells/kg. Thirteen and 25% of patients, respectively, underwent a second mobilization with cyclophosphamide þ G-CSF. After this second procedure, no patient in arm A and only 1 in arm B had yields o 2 Â 10 6 cells/kg, and 5% of patients in arm A and 6 % of patients in arm B had yields o5 Â 10 6 cells/kg precluding a tandem transplant procedure, if needed.
Of the evaluable population, 200 (82.6%) and 207 (86.2%) patients who had received VAD and bortezomib-dexamethasone induction, respectively, underwent a first ASCT. Thus, despite adequate stem cell collection, high-dose melphalan and ASCT were not performed in 34 patients, due to progressive disease (15 cases), patient's refusal (3), renal function impairment (2), severe infections (6), poor performance status (4), respiratory failure (2), precluding high-dose therapy or toxic deaths after stem cell mobilization (2) . A median number of 3.77 and 3.16 Â 10 6 CD34 þ cells/kg were infused in patients enrolled in arm A and arm B, respectively, during the first ASCT procedure (Table 2 ). There was no difference regarding duration of hospitalization, duration of neutropenia or thrombocytopenia, transfusion requirements, duration of G-CSF administration or antibiotic uses in the 2 arms of the trial. Two toxic deaths were observed in arm A (1%) versus 1 in arm B (0.5%). A better response rate following the ASCT was observed in bortezomib-dexamethasone arm, and results for Abbreviations: G-CSF, granulocyte-colony-stimulating factor; VAD, vincristine-doxorubicin-dexamethasone. Letters to the Editor outcome and for the need of a second ASCT will be reported in depth elsewhere. 3 The IFM2005-01 trial showed the superiority of bortezomibdexamethasone over VAD before ASCT. Other recent studies also indicate that this combination is highly effective [4] [5] [6] and could be considered as the backbone of induction regimens before high-dose therapy. [7] [8] [9] We here report that a single mobilization with G-CSF was adequate and allowed the harvest of a sufficient number of CD34 þ cells for a single transplant in 97% and for a tandem transplant in 77% of the patients treated upfront with bortezomib-dexamethasone. Thus, less than one-fourth of the patients of the bortezomib-dexamethasone arm required subsequent potentially toxic chemomobilization with cyclophosphamide plus G-CSF to reach the target yield of 5 Â 10 6 CD34 þ cells/kg. In comparison with VAD, the median number of CD34 þ cells harvested in the bortezomibdexamethasone arm was significantly lower without impairing the ability of performing ASCT. An identical number of patients in both arms of the study (98 and 97%, respectively) had yields 42 Â 10 6 CD34 þ cells/kg high enough to perform a single ACST, but a higher number of patients in the bortezomibdexamethasone arm required a second mobilization using cyclophosphamide plus G-CSF to reach the target of 5 Â 10 6 CD34 þ cells/kg. This is not surprising as doxorubicin infused with the VAD regimen induces some degree of cytopenia improving stem cell harvest after G-SCF priming. The course of the first ASCT was very similar across the two arms of the study, despite a lower median number of CD34 þ cells infused in the bortezomib-dexamethasone arm. Hematologic recovery was identical as well as transfusion requirements and duration of hospitalization.
This study, the largest one reporting on stem cell collection after bortezomib-dexamethasone as induction prior to ASCT, provides important informations for the management of myeloma patients treated with high-dose therapy in the era of novel agents.
